“Efficacy and Safety of Tyrosine Kinase 2 Inhibitor Deucravacitinib in Psoriasis : A Systematic Review and Drug-Response Meta Analysis of RCTs” (2025) JIMKI: Jurnal Ilmiah Mahasiswa Kedokteran Indonesia, p. 10. doi:10.53366/jimki.vi.961.